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Abstract
Background:  Childhood pre-B acute lymphoblastic leukemia (ALL) is a bone marrow (BM)
derived disease, which often disseminates out of the BM cavity, where malignant cells to a variable
degree can be found circulating in the peripheral blood (PB). Normal pre-B cells are absolutely
dependent on BM stroma for survival and differentiation. It is not known whether transformed pre-
B ALL cells retain any of this dependence, which possibly could impact on drug sensitivity or MRD
measurements.
Results: Pre-B ALL cells, highly purified by a novel method using surface expression of CD19 and
immunoglobulin light chains, from BM and PB show a very high degree of similarity in gene
expression patterns, with differential expression of vascular endothelial growth factor (VEGF) as a
notable exception. In addition, the cell sorting procedure revealed that in 2 out of five investigated
patients, a significant fraction of the malignant cells had matured beyond the pre-B cell stage.
Conclusion: The transition of ALL cells from the BM into the circulation does not demand, or
result in, major changes of gene expression pattern. This might indicate an independence of BM
stroma on the part of transformed pre-B cells, which contrasts with that of their normal
counterparts.
Background
Children suffering from acute lymphoblastic leukemia, in
the recent past an inevitably fatal disease, have experi-
enced a dramatically improved outcome during the past 4
decades, such that four out of five newly diagnosed pedi-
atric patients today can expect to be cured [1-6]. However,
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in order to further improve the prognosis for children
with ALL, it is crucial to learn more about the molecular
consequences and causes of malignant transformation. In
addition to leading to an uncontrolled cell growth of pre-
B ALL cells, transformation also results in a pronounced
block of cell differentiation. This developmental distur-
bance is also reflected in the primary anatomical location
of the leukemic cells being the bone marrow (BM), which
also is the primary site for normal progenitor B-lym-
phocytes. Hence, it is reasonable to assume that the trans-
formed cells in general maintain several of the features of
the B-cell progenitors and thus utilize the presence of
growth factors in the BM in a fashion similar to a normal
cell. However, even though the BM is the primary site for
leukemic cells, extramedullary locations, including
peripheral blood (PB), often contains cells related to the
malignant clone in the BM. Given the requirement of
stroma signalling for normal pre-B cells, it is not obvious
that ALL cells residing in the BM are similar to ALL cells in
the circulation. Malignant cells in these two locations
could differ with regard to differentiation stage, cell cycle
status or proneness to apoptosis, which might influence
drug sensitivity and thus also minimal residual disease
(MRD) measurements.
In order to establish the relationship between ALL cells in
the BM and in the PB, and to resolve how the anatomical
location is reflected in the overall gene expression pattern
of a pre-B ALL cell, we developed a purification approach
based on the presumption that the transformed cells
express the lineage marker CD19, but due to the develop-
mental block lack the expression of Immunoglobulin
light chain (IgL) protein, normally not expressed until
later stages of development [7], on the cell surface. This
allowed us to purify leukemic cells from both BM and PB
in the same patients, and subsequent gene expression
analysis revealed that the overall gene expression pattern
in transformed cells in PB overlaps with that of phenotyp-
ically similar cells in the BM. These data suggest the ability
of leukemic blasts to migrate freely independently of any
putative niche otherwise restricting normal pre-B cells to
the BM.
Patients and methods
Patients
BM and PB were obtained at diagnosis and at remission
from five children with ALL, and three children diagnosed
with non-malignant disease, after informed consent and
with the approval of the research ethics committee at
Lund University. Patients were selected based on availa-
bility of enough cells after diagnostic work-up, and on the
presence of a chromosomal aberration, which could be
detected by FISH.
Cell separation, phenotyping, and sorting
BM and PB mononuclear cells were isolated, frozen/
thawed and stained as previously described [8]. Cells were
stained with anti-CD19-allophycocyanin (APC), anti-κ-
fluorescein isothiocyanate (FITC) and anti-λ-phycoeryth-
rin (PE), all from Becton Dickinson (BD). Dead cells were
excluded by staining with 7-aminoactinomycin D (7-
AAD, Sigma). Cells were sorted on a FACS DiVa cell sorter
(BD), and data analysis was done with the Cell Quest
(BD) software.
FISH analyses
Interphase FISH analyses were performed as previously
described[8], using commercially available probes (Vysis)
for the respective genetic abnormalities, i.e., ETV6  for
dic(7;12)(p11;p11) (resulting in loss of the ETV6 gene),
ETV6/RUNX1  for t(12;21)(p13;q22), TCF3  for
t(1;19)(q23;p13), and a chromosome 21 probe for high
hyperdiploidy (> 50 chromosomes. 200–300 nuclei were
analyzed in each sample.
Microarray
RNA was extracted as previously described [9], labeled
and amplified according to Affymetrix™; Small Sample
Labeling Protocol v.2. Affymetrix HG-U133 plus 2.0
Chips were normalized using invariant set normalization
and probe level expression values were calculated using
the PM-MM model provided by the dCHIP software [10].
Q-PCR
RNA was isolated by sorting of cells into RLT buffer for
subsequent RNA purification using the RNAeasy kit (Qia-
gen Inc) according to the manufacturers instructions for
RNA purification from 10 000 cells. cDNA was generated
by annealing total RNA from 10 000 cells to 0,5 μg of ran-
dom hexamers in 10 μl DEPC-treated water. Reverse tran-
scriptase reactions were performed with 200 units of
SuperScript Reverse Transcriptase (Life Technologies) in
the manufacturers' buffer supplemented with 0,5 mM
dNTP, 10 mM DTT and 20 units RNase inhibitor (Boer-
inger Mannheim, Bromma, Sweden) in a total volume of
20 μl. The real-time polymerase chain reaction (PCR) was
based on the Taqman™ technology (Applied Biosystems,
Stockholm, Sweden). The threshold cycles (Ct) for the
endogenous control HPRT mRNA and the target signals
were determined and the relative RNA quantification was
calculated using the comparative Ct method as 2-ΔCt where
ΔCt is Ct (target)-Ct (HPRT).
Oligonucleotides for quantitative Taqman™ real time PCR
were ordered as Assay on demand (Applied Biosystems).
TaqMan® probes used were: HPRT1 (Hs99999909_m1)
and VEGF (Hs00900055_m1).Molecular Cancer 2008, 7:67 http://www.molecular-cancer.com/content/7/1/67
Page 3 of 6
(page number not for citation purposes)
Results and discussion
Cell sorting based on Ig-light chain expression on B-lineage 
cells allows for the purification of pre-B ALL cells
In order to perform a valid comparison of gene expression
patterns in BM-derived leukemic cells to those derived
from PB, we needed to establish a protocol that would
allow us to identify and purify leukemic cells in BM and
PB. We also wanted to sort a comparable cell population
from BM of the same patients in remission, both in order
to identify tumor-specific features and to obtain an
impression of the effect that the genetic background
might have on the gene expression patterns in the normal
regenerating BM. In order to achieve this we used the fact
that IgL typically is not rearranged, and thus not expressed
on the cell surface, until the immature B-cell stage [7] (Fig-
ure 1A), and since pre-B ALL cells are blocked in their dif-
ferentiation prior to that stage they would not be expected
to display any IgL on the cell surface. Hence, we sorted
mononuclear cell preparations from BM and PB from five
patients based on positive expression of the B-lineage
marker CD19 and lack of expression of surface IgL (Figure
1B). The percentage of CD19 positive cells varied from 63
to 91 percent in BM (Table 1), and from 9.2 to 82% in PB
(Table 1). A minor part (2–15%) of the BM CD19+ cells
also expressed IgL chains (Table 1) while the percentage of
IgL positive cells varied from 5 to 90% in the PB. These
data show that the composition of cells in BM and PB at
the time of diagnosis is highly variable, and thus highlight
the need for purification of cells before any relevant com-
parisons of function or gene expression patterns can be
made. All the investigated samples carried chromosomal
aberrations which allowed us to analyze the clonal
involvement of the sorted cell populations at a single cell
level by FISH. This revealed that while the percentage of
cells carrying a chromosomal abnormality in the IgL pos-
itive fractions varied from 1.5 to 33%, the FISH positive
fraction of the IgL negative cells was between 96 and
100%. When comparing BM and PB cells from individual
patients, it is of note that the surface expression pattern of
CD19 and IgL characteristic of pre-B cells is retained in
extramedullary circulating leukemic blasts. Interestingly,
in some of the patients the leukemic clone contained a
significant fraction of cells expressing an IgL, indicating
developmental progression into the B cell stage, and sug-
gesting that the developmental block is incomplete.
ALL cells from BM and PB display a common but patient 
specific transcriptome
Having established a protocol with which tumor cells can
be purified from both BM and PB to almost homogeneity,
Table 1: Clonal involvement of sorted IgL+ and IgL- cells.
Patient Translocation %CD19+ cells
 of all BM MNCs
%IgL+ cells of
 all CD19+ cells
Population % FISH+
A dic(7;12)(p11;p11) 76 15 CD19+IgL- 99
CD19+IgL+ 1,9
B t(12;21)(p13;q22) 63 12 CD19+IgL- 99
CD19+IgL+ 2,7
C t(1;19)(q23;p13) 84 7 CD19+IgL- 98
CD19+IgL+ 27
D High
hyperdiploidy
87 7 CD19+IgL- 99
CD19+IgL+ 25
E t(12;21)(p13;q22) 91 2 CD19+IgL- 100
CD19+IgL+ 3
Patient WBC ×109/l %CD19+ cells 
of all PB MNCs
%IgL+ cells of
 all CD19+ cells
Population % FISH+
A3 . 5 5 4 5 2 C D 1 9 +IgL- 97
CD19+IgL+ 4,2
B 2.1 9,2 90 CD19+IgL- ND
CD19+IgL+ ND
C7 0 5 7 2 0 C D 1 9 +IgL- 96
CD19+IgL+ 33
D2 3 8 1 1 2 C D 1 9 +IgL- 99
CD19+IgL+ 17
E2 9 8 2 5 C D 1 9 +IgL- 100
CD19+IgL+ 8
MNCs from five patients (A-E) analyzed for phenotype by FACS and clonal involvement in IgL+ and IgL- cells by detection of the corresponding 
chromosome abnormality by FISH. Upper panel shows data from BM at diagnosis and lower panel from PB at diagnosis.Molecular Cancer 2008, 7:67 http://www.molecular-cancer.com/content/7/1/67
Page 4 of 6
(page number not for citation purposes)
we next performed gene expression micro-array analysis,
using Affymetrix, to compare the global gene expression
pattern between leukemic cells harvested from BM and PB
in three of the patients (Figure 2A and 2B). In addition, we
sorted CD19+IgL- BM cells for micro array analysis from
the same three patients when in clinical and molecular
(RT-PCR) remission for use as a normal reference. Analy-
sis of the data revealed highly related expression patterns
in cells obtained from all three patients in remission, sug-
gesting that the impact of patient specific genetic variation
on gene expression patterns in these cells is low (Figure 2A
and 2B). In contrast, the expression profiles between
patient samples at diagnosis showed significant differ-
ences, in line with observed differences between sub-
groups of ALL previously published [11-13]. Within the
same patient, however, the expression patterns between
BM and PB cells were almost identical (Figure 2A and 2B),
suggesting that the different location of the cells do not
involve any major changes in the transcriptome, and fur-
ther supports the idea that exit from the bone marrow
environment does not involve major changes of the cellu-
lar phenotype.
VEGF is differentially expressed in BM as compared to PB 
pre-B ALL cells
In order to identify genes with differential expression pat-
terns associated with the anatomical location, we
searched the data set for genes with an expression differ-
ence greater than a factor two on comparison between
diagnostic BM and PB across all three patients. The single
transcript fulfilling these criteria was coding for vascular
endothelial growth factor (VEGF), with an elevated
expression in BM as compared to PB. In order to verify and
extend this finding, we analysed the expression of VEGF
by Q-PCR analysis of RNA from purified leukemic BM and
PB cells from patient A, C, D and E (Figure 2C) (Patient B
could not be analyzed due to lack of material). These
experiments verified that the expression level of VEGF was
reduced in PB as compared to BM in all the patients. The
relative levels of VEGF transcripts in the BM were, how-
ever, largely different between patients, arguing against a
general super activation of VEGF in pre-B ALL BM cells. In
order to investigate if this differential expression pattern is
a common phenomena or something related to ALL, we
analysed the expression of VEGF in CD19+IgL- cells in the
BM and PB from children with other diagnoses (vasculitis,
Mb Gaucher and post infectious peripheral neutropenia)
(Figure 2D). In all three cases VEGF expression was com-
Sorting of pre-B and immature B cells Figure 1
Sorting of pre-B and immature B cells. Panel (A) dis-
play a schematic drawing of the B-lymphoid developmental 
pathway. (B) Representative FACS plot of BM MNCs from a 
pediatric patient diagnosed with a pre-B ALL, stained with 
antibodies against CD19 and IgL (κ and λ). Gates for sorting 
are depicted.
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Microarray analysis of patient samples Figure 2
Microarray analysis of patient samples. (A) Hierarchi-
cal clustering of gene expression data obtained from purified 
diagnostic blood (PBd) and bone marrow (BMd) as well as 
remission BM (BMr) cells from three investigated patients A-
C. (Genes used for clustering satisfied the following two cri-
terions; > 0.5 SD/MEAN across samples, and ≥ 100 expres-
sion units in ≥ 10% of arrays used.) (B) Overall hierarchical 
relationship in gene expression patterns between the sam-
ples. (C) Q-PCR analysis of normalized expression levels of 
VEGF in BMd and PBd in 4 patients (A, C-E). The data pre-
sented is triplicates from one representative out of two 
experiments. Error bars indicate standard deviation. (D) Q-
PCR analysis of normalized expression levels of VEGF in BM 
and PB in 3 patients diagnosed with other disease than ALL. 
Mb Gauchers (MbG), Post Infection (PI) or Vasculitis (VA) as 
indicated. The data presented is triplicates and error bars 
indicate standard deviation.
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parable or higher in the PB than in the BM. This indicates
that the higher level of VEGF expression in BM is restricted
to ALL. An elevated VEGF expression in BM as compared
to PB is an intriguing finding in light of recent observa-
tions of an autocrine survival loop that involves VEGF in
normal HSCs [14] as well as in acute leukemias [15], and
with an increased production of B-cells upon continuous
VEGF stimulation [16]. The difference in expression level
could indicate a segregation of the leukemic blasts into
mitotically more active cells residing in the BM, or it could
be an effect caused by relative hypoxia in the ALL BM,
which induces VEGF transcription through hypoxia-
inducible factor 1 (HIF-1) [17].
Conclusion
We here report a protocol for purification of ALL cells
from different anatomical localisations, which we in the
present work has used to compare gene expression pat-
terns in leukemic blasts harvested from BM and PB. This
comparison revealed that transition of ALL cells from the
bone marrow to the circulation is not a result of, or con-
tributes to, progressed differentiation, but rather suggests
an inherent ability of leukemic blasts to exist in a micro-
environment not supportive for normal cells at a corre-
sponding maturational stage. Further, the sorting of
CD19+ lymphoid cells at different maturational stages, as
defined by the presence or absence of IgL, followed by sin-
gle cell analysis of leukaemia specific chromosomal aber-
rations by FISH, interestingly revealed that both blood
and BM from two of the patients (C and D) contained a
significant fraction of clonal IgL+ cells. This indicates that
ALL cells may not always be as stringently blocked in
development as commonly thought, but may retain some
ability to progress beyond the pre-B cell stage into more
mature stages of development.
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